Lumithera Valeda Treatment for AMD Coming to Bay Area Retina Associates

WALNUT CREEK, CALIFORNIA - Bay Area Retina Associates (BARA) is pleased to be among the first retina specialty groups in the Bay Area to offer patients access to the Lumithera Valeda treatment for dry age-related macular degeneration (AMD).

Until now, no direct treatment has been available for dry AMD, except for injections into the eye for advanced cases. With FDA approval in late 2024, the Lumithera Valeda is the first and only non-invasive treatment for dry AMD. The Valeda uses photobiomodulation (PBM), a safe form of light therapy, to treat the retina. In clinical trials, patients who received Valeda treatment experienced a significant improvement in vision compared to those who did not receive treatment.

Patients with specific retinal findings and vision between 20/32 and 20/70 may be eligible for treatment in one or both eyes. An evaluation by a retina specialist is essential to determine eligibility. All BARA physicians are trained to assess AMD and identify candidates for treatment. The treatment consists of a cycle of nine short light therapy sessions over three to four weeks and can be repeated every four months.

For more information or to make an appointment with a BARA retina specialist to determine eligibility for Valeda treatment, please call (800) 5-RETINA (573-8462).

About Bay Area Retina Associates

Bay Area Retina Associates is a group practice of retinal surgeons who have served the Bay Area community for 35 years. All members of the group are board-certified by the American Board of Ophthalmology and have completed fellowship training in the medical and surgical care of retinal diseases. All BARA surgeons have expertise in the treatment of common diseases such as age-related macular degeneration, diabetic retinopathy, and retinal detachment, as well as rare diseases.